The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 25, 2014
Filed:
May. 25, 2012
C. Frank Bennett, Carlsbad, CA (US);
Ayelet Chajut, Ramat Hasharon, IL;
Christine Esau, La Jolla, CA (US);
Eric Marcusson, San Francisco, CA (US);
Noga Yerushalmi, Nes Ziona, IL;
C. Frank Bennett, Carlsbad, CA (US);
Ayelet Chajut, Ramat Hasharon, IL;
Christine Esau, La Jolla, CA (US);
Eric Marcusson, San Francisco, CA (US);
Noga Yerushalmi, Nes Ziona, IL;
Regulus Therapeutics, Inc., San Diego, CA (US);
Rosetta Genomics Ltd, Rehovot, IL;
Abstract
Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.